 |
| Press Release dated March 31, 2005 |
|
Company’s restructuring concluded, sales growth of 5%, result almost in balance and equity ratio increased to 76%
aap Implantate AG, a medical technology company, operating in the fields of implants for healing bone fractures and joint replacements, bone cement and cementing techniques as well as bone replacement substances and antibiotical carriers, achieved in the financial year 2004, despite the financial and operative restructuring of the company, a sales growth of 5.2% to EUR 11.5 million (previous year: EUR 11.0 million).
The financial year 2004 of aap • mebio was significant affected by the implementation of restructuring measures (a EUR 9.7 million capital increase, liabilities decreased by EUR 13.9 million, value adjustments totaling EUR 4.9 million). Disregarding the extraordinary restructuring-related result of EUR 2.5 million, the Group’s EBITDA in the financial year 2004 was EUR 1.2 million (previous year: EUR minus 273,000). EBIT at EUR minus 316,000 was well above the previous year’s EUR minus 4.6 million.
Group’s result for the year improved to EUR minus 140,000 (previous year: EUR minus 15.4 million). With a balance sheet total of EUR 20.4 million (previous year: EUR 26.7 million) the equity ratio increased to 76% (previous year: 25%).
For further information, please contact:
aap Implantate AG | | | Lorenzweg 5 | | | D-12099 Berlin | | | X | | | Oliver Bielenstein | Nanette Hüdepohl | | Director/CFO | Investor & Public Relations | Tel.: +49 30 750 19 - 140 | Tel.: +49 30 75019 - 133 | Fax: +49 30 750 19 - 290 | Fax: +49 30 75019 - 290 | | X | | | WKN 506660, ISIN DE0005066609 | | | Prime Standard/Regulated Market | | | Traded at all German Stock Exchanges | |
|
|
|
Print this page
